A Review on the Association between Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
There is a concern on the risk of thyroid cancer associated with glucagon-like peptide-1 (GLP-1) analogs including liraglutide and exenatide. In this article, we review related experimental studies, clinical trials and observational human studies currently available. In rodents, liraglutide activated the GLP-1 receptors on C-cells, causing an increased incidence of C-cell neoplasia. Animal experiments with monkeys demonstrated no increase in calcitonin release and no C-cell proliferation after long-term liraglutide administration. Longitudinal 2-year data from clinical trials do not support any significant risk for the activation or growth of C-cell cancer in humans in response to liraglutide. However, an analysis of the FDA adverse event reporting system database suggested an increased risk for thyroid cancer associated with exenatide after its marketing. Noticeably, a recent study discovered that GLP-1 receptor could also be expressed in human papillary thyroid carcinomas (PTC), but the impact of GLP-1 analogs on PTC is not known. Therefore, GLP-1 analogs might increase the risk of thyroid C-cell pathology in rodents, but its risk in humans awaits confirmation. Since GLP-1 receptor is also expressed in PTC besides C-cells, it is important to investigate the actions of GLP-1 on different subtypes of thyroid cancer in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“but these effects are smaller in humans.5”
From Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials (2024) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129 · cited 1×
“For examples some clinical trials have suggested an association between pioglitazone and bladder cancer [26, 27].”
BackgroundGiovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366 · cited 1×
“Hindawi Publishing Corporation Experimental Diabetes Research Volume 2012, Article ID 924168, 7 pages doi:10.1155/2012/924168 Review Article”
BackgroundInfluentialNauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · cited 4×
“While GLP-1 analogs can efficiently reduce blood glucose level in patients with type-2 diabetes [3, 4], they may potentially have adverse effects on thyroid glands because GLP-1 receptors are expressed in thyroid glands of humans [10] as well as in those of rodents [11].”
BackgroundInfluentialVigneri, P., Frasca, F., Sciacca, L., Pandini, G., & Vigneri, R. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0087 · Cited by 1,009
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944
Mojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 882 · cited 1×
“Glucagon-like peptide-1 (GLP-1) is an incretin hormone released after meals by L cells in the ileum [1].”
BackgroundKnudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 700 · cited 1×
“Hindawi Publishing Corporation Experimental Diabetes Research Volume 2012, Article ID 924168, 7 pages doi:10.1155/2012/924168 Review Article”
BackgroundInfluentialBjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672
Hay, I. D. (1990) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30310-4 · Cited by 634
Elisei, R., Bottici, V., Luchetti, F., Di Coscio, G., Romei, C., Grasso, L., Miccoli, P., Iacconi, P., Basolo, F., Pinchera, A., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030550 · Cited by 537 · cited 8×
“[10] B. Gier, P. C. Butler, C. K. Lai, D. Kirakossian, M. M. DeNicola, and M. W. Yeh, “Glucagon like peptide-1 receptor expression in the human thyroid gland,” Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 1, pp. 121–131, 2012.”
BackgroundInfluentialAgersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510 · cited 1×
“Hindawi Publishing Corporation Experimental Diabetes Research Volume 2012, Article ID 924168, 7 pages doi:10.1155/2012/924168 Review Article”
BackgroundInfluentialKolterman, O. G., Kim, D. D., Shen, L., Ruggles, J. A., Nielsen, L. L., Fineman, M. S., & Baron, A. D. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.2.173 · Cited by 434 · cited 1×
“3–4 hours [6], exenatide has to be injected subcutaneous twice a day.”
BackgroundCostante, G., Meringolo, D., Durante, C., Bianchi, D., Nocera, M., Tumino, S., Crocetti, U., Attard, M., Maranghi, M., Torlontano, M., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1590 · Cited by 372 · cited 1×
“…Department of Internal Medicine, National Taiwan University College of Medicine, Taipei 10002, Taiwan 2 Division of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, Taipei 10002, Taiwan Correspondence should be addressed to Chin-Hsiao Tseng,…”
BackgroundWeighing Risks and Benefits of Liraglutide — The FDA's Review of a New Antidiabetic Therapy
Parks, M., & Rosebraugh, C. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1001578 · Cited by 275 · cited 1×
“In preclinical animal studies, rodents treated with liraglutide would have a higher incidence of C-cell tumor formation and focal hyperplasia [12, 13].”
BackgroundMadsen, K., Knudsen, L. B., Agersoe, H., Nielsen, P. F., Thøgersen, H., Wilken, M., & Johansen, N. L. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070861j · Cited by 244
Dormandy, J., Bhattacharya, M., & van Troostenburg de Bruyn, A.-R. (2009) · Drug Safety · doi:10.2165/00002018-200932030-00002 · Cited by 227
Mortality and Causes of Death in a National Sample of Diabetic Patients in Taiwan
Tseng, C.-H. (2004) · Diabetes Care · doi:10.2337/diacare.27.7.1605 · Cited by 226 · cited 1×
“Diabetes is also one of the leading causes of death nowadays [15].”
BackgroundSelf-citationIncretin-Based Therapies in Type 2 Diabetes Mellitus
Chia, C. W., & Egan, J. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2109 · Cited by 223
Hegedüs, L., Moses, A. C., Zdravkovic, M., Le Thi, T., & Daniels, G. H. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2318 · Cited by 194 · cited 1×
“Calcitonin, a hormone secreted by thyroid C cells, is regarded as an important clinical biomarker for C-cell diseases such as medullary thyroid carcinoma (MTC) and hereditary Ccell hyperplasia because of its high sensitivity and specificity [28–30].”
BackgroundMadsen, L. W., Knauf, J. A., Gotfredsen, C., Pilling, A., Sjögren, I., Andersen, S., Andersen, L., Sietske de Boer, A., Manova, K., Barlas, A., et al. (2012) · Endocrinology · doi:10.1210/en.2011-1864 · Cited by 161 · cited 1×
“[33] documented that C-cell hyperplasia and calcitonin release associated with GLP-1 agonists in wildtype mice were GLP-1-receptor dependent.”
BackgroundGlucagon Like Peptide-1 Receptor Expression in the Human Thyroid Gland
Gier, B., Butler, P. C., Lai, C. K., Kirakossian, D., DeNicola, M. M., & Yeh, M. W. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2407 · Cited by 157
Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan
Tseng, C. (2011) · Diabetologia · doi:10.1007/s00125-011-2171-z · Cited by 142 · cited 1×
“Hindawi Publishing Corporation Experimental Diabetes Research Volume 2012, Article ID 924168, 7 pages doi:10.1155/2012/924168 Review Article”
BackgroundInfluentialSelf-citationSimonsen, L., Holst, J. J., & Deacon, C. F. (2006) · Diabetologia · doi:10.1007/s00125-005-0128-9 · Cited by 133 · cited 1×
“With elimination by glomerular filtration [5] and a mean half-life of 3.”
BackgroundIncreasing incidence of diagnosed type 2 diabetes in Taiwan: analysis of data from a national cohort
Tseng, C., Tseng, C. P., Ck, C., Huang, T.-P., Song, Y.-M., Chou, C. ‐., Lai, S.-M., Tai, T. Y., & Cheng, J. (2006) · Diabetologia · doi:10.1007/s00125-006-0314-4 · Cited by 124 · cited 1×
“Both the prevalence and incidence of diabetes have been increasing dramatically in recent decades, especially in the Asian people [14].”
BackgroundSelf-citationDiabetes and Risk of Prostate Cancer
Tseng, C.-H. (2011) · Diabetes Care · doi:10.2337/dc10-1640 · Cited by 123 · cited 1×
“Hindawi Publishing Corporation Experimental Diabetes Research Volume 2012, Article ID 924168, 7 pages doi:10.1155/2012/924168 Review Article”
BackgroundInfluentialSelf-citationPioglitazone and Bladder Cancer
Tseng, C.-H. (2012) · Diabetes Care · doi:10.2337/dc11-1449 · Cited by 123
Self-citationMachens, A., Hoffmann, F., Sekulla, C., & Dralle, H. (2009) · Endocrine-Related Cancer · doi:10.1677/erc-09-0136 · Cited by 83 · cited 8×
“[10] B. Gier, P. C. Butler, C. K. Lai, D. Kirakossian, M. M. DeNicola, and M. W. Yeh, “Glucagon like peptide-1 receptor expression in the human thyroid gland,” Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 1, pp. 121–131, 2012.”
BackgroundInfluentialLamari, Y., Boissard, C., Moukhtar, M. S., Jullienne, A., Rosselin, G., & Garel, J.-M. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)00895-2 · Cited by 73 · cited 1×
“Several in vitro studies employing rat thyroid C-cell lines and thyroid tissues have demonstrated that activation of the GLP-1 receptor leads to calcitonin secretion, which is attenuated by the GLP-1 receptor antagonist exendin (9–39) [31, 32].”
BackgroundTseng, C. (2010) · Gut · doi:10.1136/gut.2010.226522 · Cited by 73 · cited 1×
“Hindawi Publishing Corporation Experimental Diabetes Research Volume 2012, Article ID 924168, 7 pages doi:10.1155/2012/924168 Review Article”
BackgroundInfluentialSelf-citationCrespel, A., De Boisvilliers, F., Gros, L., & Kervran, A. (1996) · Endocrinology · doi:10.1210/endo.137.9.8756532 · Cited by 67
Tseng, C., Chong, C.-K., & Tai, T. Y. (2008) · Diabetologia · doi:10.1007/s00125-008-1204-8 · Cited by 60 · cited 1×
“Hindawi Publishing Corporation Experimental Diabetes Research Volume 2012, Article ID 924168, 7 pages doi:10.1155/2012/924168 Review Article”
BackgroundInfluentialSelf-citationTseng, C.-H., Chong, C.-K., Tseng, C.-P., & Chan, T.-T. (2009) · Annals of Medicine · doi:10.1080/07853890902729778 · Cited by 51
Self-citationTseng, C. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr334 · Cited by 43 · cited 1×
“Hindawi Publishing Corporation Experimental Diabetes Research Volume 2012, Article ID 924168, 7 pages doi:10.1155/2012/924168 Review Article”
BackgroundInfluentialSelf-citationTseng, C. (2011) · Annals of Medicine · doi:10.3109/07853890.2010.530683 · Cited by 41 · cited 1×
“Hindawi Publishing Corporation Experimental Diabetes Research Volume 2012, Article ID 924168, 7 pages doi:10.1155/2012/924168 Review Article”
BackgroundInfluentialSelf-citation
Research works printed but not linked: 1
- 10.1210/en.137.9.3674 · doi:10.1210/en.137.9.3674 · Paper page
Cited by
Regulation of Glucose Homeostasis by GLP-1
Nadkarni, P., Chepurny, O. G., & Holz, G. G. (2014) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-800101-1.00002-8 · Cited by 287
Incretins: their physiology and application in the treatment of diabetes mellitus
Tasyurek, H. M., Altunbas, H. A., Balci, M. K., & Sanlioglu, S. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2501 · Cited by 121
“Consequently, it is essential to carefully follow up diabetic patients exposed to long-term GLP-1 analogues for any incidence of thyroid cancer [184].”
BackgroundPanickar, K. S. (2012) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201200431 · Cited by 126
Silverii, G. A., Monami, M., Gallo, M., Ragni, A., Prattichizzo, F., Renzelli, V., Ceriello, A., & Mannucci, E. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15382 · Cited by 113
“As an exploratory post hoc analysis, we also grouped all the thyroid cancers excluding those reported as MTCs, observing a significant effect of GLP-1RA treatment (MH-OR 1.51 [95% CI 1.00, 2.29]; P = 0.05, FIGURE 1 Risk of overall thyroid cancers in patients receiving glucagon-like peptide-1 receptor agonist (GLP-1RA)…”
InfluentialDigging deeper through glucose metabolism and its regulators in cancer and metastasis
Ghanavat, M., Shahrouzian, M., Zayeri, Z. D., Banihashemi, S., Kazemi, S. M., & Saki, N. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118603 · Cited by 103
Metadata
- Authors
- Chiu, W.-Y., Shih, S.-R., & Tseng, C.-H.
- Affiliations
- National Taiwan University (TW)
- Corresponding author
- Tseng, Chin-Hsiao
- Venue
- Experimental Diabetes Research
- Publisher
- Wiley
- Published
- 2012
- Volume
- 2012
- Pages
- 1-7
- ISSN
- 1687-5214 (ISSN-L)
- 1687-5303
- PMC
- PMC3368340
- OpenAlex
- W2020816546
- Cited by
- 63
- References
- 35
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 6 · 2023: 9 · 2021: 3 · 2020: 3 · 2019: 1 · 2018: 2 · 2017: 2 · 2016: 8 · 2015: 4 · 2014: 3 · 2013: 10 · 2012: 1
- FWCI
- 0.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Experimental Diabetes Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Keywords
- GLP-1 receptor agonists, thyroid cancer, liraglutide, exenatide, GLP-1 receptor, drug safety, adverse drug reactions, calcitonin, type 2 diabetes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Animals, Clinical Trials as Topic, Diabetes Mellitus, Disease Models, Animal, Gene Expression Regulation, Humans, Macaca fascicularis, Peptides, Thyroid Neoplasms, Venoms, Receptors, Glucagon, Diabetes Complications, Mice, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.